Livzon Pharmaceutical Group continues A-share repurchases, H-shares stable

Livzon Pharmaceutical Group announced a repurchase of 48,600 A-shares on September 1, 2025, for a total of RMB 2,020,801. The repurchased A-shares were bought at prices ranging from RMB 40.43 to RMB 41.99 per share.

As of August 31, 2025, the company had repurchased a total of 13,383,055 A-shares, representing 1.48% of its total share capital. The highest price paid for A-shares was RMB 41.99, and the lowest was RMB 33.21, utilizing RMB 490,929,437.15 of funds, excluding transaction costs. These A-share repurchases are intended for cancellation to reduce the company's registered capital.

Despite the significant A-share repurchase activity, the company's H-share capital remained unchanged. The company's general mandate for H-share repurchases had not been utilized as of August 31, 2025. The total number of issued H-shares remained at 299,807,117 as of September 1, 2025, with no change in the issued share capital for this class.